Gain Therapeutics (GANX) Total Debt (2020 - 2026)

Gain Therapeutics has reported Total Debt for 7 years, with the latest figure at $343686.0 in Q2 2026.

• On a quarterly basis, Total Debt fell 23.87% year-over-year to $343686.0 in Q2 2026; TTM through Jun 2026 was $343686.0, a 23.87% decrease from a year earlier, with the FY2025 full-year figure at $400953.0, down 8.56% from the prior year.
• Total Debt was $343686.0 for Q2 2026 at Gain Therapeutics, down from $373546.0 in the prior quarter.
• The five-year high for Total Debt was $647513.0 in Q1 2022, with the low at $343686.0 in Q2 2026.
• Average Total Debt over 5 years is $504923.9, with a median of $501047.0 recorded in 2024.
• The sharpest annual moves came in 2023 and 2026: Total Debt fell 5.89% in 2023, then dropped 23.87% in 2026.
• Over 5 years, Total Debt stood at $603393.0 in 2022, then dropped by 5.89% to $567850.0 in 2023, then retreated by 22.78% to $438504.0 in 2024, then dropped by 8.56% to $400953.0 in 2025, then retreated by 14.28% to $343686.0 in 2026.
• The last three Total Debt figures came in at $343686.0 (Q2 2026), $373546.0 (Q1 2026), and $400953.0 (Q4 2025), per Business Quant data.